Jaysuing Pain Relief Knee Patches

Dosage for Artemisia Argyi Leaf extract is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity levels. There is no 'standard' dose for all patients.

Diagnostic Testing Dosage

• Prick/Puncture Testing: Usually, one drop of a 1:10 or 1:20 w/v concentration is applied to the skin. The skin is then pricked through the drop. A positive control (histamine) and negative control (saline) are used simultaneously for comparison.
• Intradermal Testing: If the prick test is negative, 0.02 mL of a highly diluted extract (e.g., 1:1000 w/v or 100 PNU/mL) may be injected into the skin to form a small bleb.

Immunotherapy Dosage (Allergy Shots)

Immunotherapy follows a two-phase dosing schedule:

1. 1Build-up Phase: Injections are typically given 1 to 3 times per week. The dose starts at an extremely low concentration (e.g., 0.05 mL of a 1:100,000 w/v dilution) and is gradually increased over several months (3 to 6 months) until a maintenance dose is reached.
2. 2Maintenance Phase: Once the effective dose is reached, the frequency of injections is reduced to once every 2 to 4 weeks. The maintenance dose is the highest dose that the patient tolerates without significant local or systemic reactions.

Artemisia Argyi Leaf extract is generally considered safe for use in children, though testing and therapy are rarely initiated in children under the age of 5. Pediatric dosing follows the same principles as adult dosing, starting with very low concentrations and titrating upward based on tolerance. Healthcare providers must exercise extreme caution in children with a history of severe asthma, as they are at higher risk for adverse reactions.

Renal Impairment

No specific dosage adjustments are provided in the manufacturer's labeling for patients with renal impairment. Because the extract is a biological protein metabolized by proteases, renal function does not typically impact the initial dosing. However, the patient's overall health status should be evaluated.

Hepatic Impairment

No dosage adjustments are required for patients with liver disease, as the liver does not play a primary role in the clearance of allergenic proteins.

Elderly Patients

Elderly patients (over 65) may have a higher prevalence of underlying cardiovascular disease. Because epinephrine is the primary treatment for an accidental overdose (anaphylaxis) during immunotherapy, and epinephrine can be risky for those with heart disease, the starting dose and rate of increase for elderly patients may be more conservative.

Artemisia Argyi Leaf extract is never self-administered at home. It must be administered in a clinical setting (such as an allergist's office) equipped with emergency supplies to treat anaphylaxis.

• Administration: Immunotherapy injections are given subcutaneously (under the skin), usually in the back of the upper arm. The site should be rotated between arms each visit.
• Observation: Patients must remain in the doctor's office for at least 30 minutes after every injection. Most fatal reactions to allergenic extracts occur within this window.
• Storage: In the clinical setting, extracts are stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They must not be frozen.

If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has passed.

• If the delay is 1 week past the scheduled date, the previous dose is usually repeated.
• If the delay is several weeks, the dose may be significantly reduced to ensure safety and prevent a systemic reaction.
• Consult your allergist immediately if you miss a scheduled injection.

An 'overdose' in the context of allergenic extracts usually refers to the administration of a dose higher than the patient's current tolerance level, which can lead to a systemic allergic reaction or anaphylaxis.

Signs of Overdose/Systemic Reaction:

• Hives (urticaria) or generalized itching.
• Swelling of the throat or tongue.
• Difficulty breathing or wheezing.
• Rapid drop in blood pressure (fainting or dizziness).
• Nausea, vomiting, or abdominal cramps.

Emergency Measures: If a systemic reaction occurs, the injection site may be slowed by a tourniquet, and epinephrine (1:1000) is administered immediately. Oxygen, antihistamines, and corticosteroids may also be used. In severe cases, emergency transport to a hospital is required.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients receiving Artemisia Argyi Leaf extract will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): The area around the injection site may turn red. This usually appears within minutes and may last for several hours.
• Local Swelling (Wheal): A small, raised bump at the injection site is common. If the swelling is larger than a half-dollar (approximately 3 cm), it should be reported to the doctor before the next dose.
• Itching (Pruritus): Intense itching at the site of injection or testing is the most frequent complaint. This is caused by the local release of histamine.
• Tenderness: The injection site may feel sore or 'bruised' for 24 to 48 hours.

• Delayed Local Reactions: Swelling or redness that appears 6 to 24 hours after the injection. These are often treated with ice packs or oral antihistamines.
• Fatigue: Some patients report feeling unusually tired or 'drained' for the remainder of the day after receiving an allergy shot.
• Mild Nasal Congestion: A slight increase in hay fever-like symptoms shortly after administration.
• Headache: Mild tension-type headaches have been reported following immunotherapy sessions.

• Lymphadenopathy: Swelling of the lymph nodes near the injection site (usually in the armpit).
• Persistent Granuloma: A small, hard, non-tender lump under the skin at the injection site that may take weeks to resolve.
• Vasovagal Reaction: Fainting due to the 'needle stick' rather than the extract itself.

> Warning: Stop taking Artemisia Argyi Leaf and call your doctor immediately if you experience any of these symptoms of a systemic reaction or anaphylaxis.

• Angioedema: Deep swelling under the skin, particularly around the eyes, lips, or throat. This can be life-threatening if it obstructs the airway.
• Generalized Urticaria: Hives that spread to parts of the body far away from the injection site.
• Wheezing or Bronchospasm: Sudden difficulty breathing or a whistling sound when you inhale/exhale, indicating an asthma-like reaction.
• Hypotension: A dangerous drop in blood pressure, characterized by extreme dizziness, confusion, or loss of consciousness.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen in the blood.

There are no known long-term 'toxic' effects of Artemisia Argyi Leaf extract when used as directed. Because it is a biological protein and not a synthetic chemical, it does not accumulate in the organs like some medications. The primary long-term effect is the intended modification of the immune system. However, some patients may develop 'serum sickness' (a delayed immune complex reaction) if very high doses are given over a long period, though this is extremely rare with modern protocols.

Allergenic extracts, including Artemisia Argyi Leaf, carry a standard FDA-mandated warning regarding the risk of severe systemic reactions.

Summary of Warning: Artemisia Argyi Leaf extract can cause severe life-threatening systemic reactions, including anaphylaxis. This product must only be administered by healthcare professionals prepared to manage such reactions. Patients with unstable asthma or those taking beta-blockers are at increased risk. Immunotherapy should be delayed if the patient is experiencing an acute asthma flare-up.

Report any unusual symptoms to your healthcare provider. Even a large local reaction (swelling of the whole arm) can be a precursor to a more serious systemic reaction at the next dose.

Artemisia Argyi Leaf extract is a potent biological agent. Its use is restricted to diagnostic and therapeutic procedures performed by trained medical personnel. It is not for self-administration. Patients must be aware that every injection carries a small but real risk of a severe allergic reaction, even if they have tolerated previous injections without issue.

No FDA black box warnings specifically unique to Artemisia Argyi Leaf exist beyond the class-wide warning for all allergenic extracts. The class warning emphasizes that:

1. 1Extremely sensitive patients may experience severe reactions.
2. 2The extract must be used with extreme caution in patients with respiratory disease.
3. 3Emergency equipment (epinephrine, airway management) must be immediately available.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Patients must be monitored for 30 minutes post-injection. If a patient experiences a systemic reaction, the immunotherapy protocol must be re-evaluated and the dose significantly reduced.
• Asthma Status: Patients with symptomatic or unstable asthma are at a much higher risk for a fatal reaction. Immunotherapy should not be administered if the patient's Peak Expiratory Flow (PEF) is significantly below their personal best or if they are experiencing an asthma exacerbation.
• Cardiovascular Disease: Patients with pre-existing heart conditions may not tolerate the stress of a systemic reaction or the effects of the epinephrine used to treat it.
• Autoimmune Disorders: There is theoretical concern that immunotherapy could worsen certain autoimmune conditions (e.g., systemic lupus erythematosus), although data are limited. Healthcare providers must weigh the benefits against the risks in these patients.

• Pre-Injection Assessment: Before every dose, the healthcare provider will ask about any 'late' reactions from the previous dose and assess the patient's current asthma symptoms.
• Post-Injection Observation: A mandatory 30-minute wait in the clinic is required.
• Lung Function: For asthmatic patients, a quick spirometry or peak flow test may be performed before the injection to ensure the lungs are stable.
• Skin Inspection: The injection site is inspected for local reactions before the patient is allowed to leave.

Artemisia Argyi Leaf extract does not typically cause sedation or cognitive impairment. However, if a patient experiences a systemic reaction (dizziness, drop in blood pressure) or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.

There is no direct chemical interaction between alcohol and Artemisia Argyi Leaf extract. However, alcohol consumption can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of absorption of the extract or mask the early signs of an allergic reaction. It is generally advised to avoid alcohol for several hours after an immunotherapy injection.

Immunotherapy is usually a long-term commitment (3 to 5 years). Stopping the treatment prematurely may result in the return of allergy symptoms. There is no 'withdrawal syndrome' associated with stopping Artemisia Argyi Leaf extract, but the immunological protection will gradually fade over time if the course is not completed.

> Important: Discuss all your medical conditions with your healthcare provider before starting Artemisia Argyi Leaf.

There are no drugs that are 'absolutely' contraindicated in a way that causes a direct chemical reaction, but certain drugs make the use of Artemisia Argyi Leaf extract unacceptably dangerous:

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These medications are used for high blood pressure and heart conditions. They are contraindicated because they block the effects of epinephrine. If a patient on a beta-blocker has an anaphylactic reaction to the Artemisia extract, the standard treatment (epinephrine) may not work, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): Some studies suggest that patients taking ACE inhibitors may be at an increased risk for more severe systemic reactions to allergenic extracts.
• Tricyclic Antidepressants (e.g., Amitriptyline): These can potentiate the effect of epinephrine, which could be problematic if epinephrine is needed to treat a reaction. However, they also have antihistamine properties that might mask early symptoms of a reaction.
• MAO Inhibitors (e.g., Phenelzine): Similar to tricyclics, these can interfere with the body's ability to process epinephrine, leading to dangerously high blood pressure if an emergency occurs.

• Antihistamines (e.g., Loratadine, Cetirizine, Diphenhydramine): While these do not make the extract dangerous, they interfere with diagnostic skin testing. Patients must stop taking antihistamines for 3 to 7 days before a skin test, or the test will likely show a 'false negative' result.
• Systemic Corticosteroids: High doses of oral steroids (like prednisone) can suppress the skin's reactivity, potentially leading to inaccurate skin test results.

There are no known direct interactions with specific foods. However, patients with a 'Mugwort-Celery-Spice Syndrome' may experience cross-reactivity. If a patient eats celery, carrots, or certain spices (like cumin or coriander) immediately before or after an Artemisia Argyi Leaf injection, it could theoretically increase the total 'allergic load' on the immune system and trigger a reaction.

• St. John's Wort: May increase sensitivity to light, but no known interaction with allergenic extracts.
• Herbal Antihistamines (e.g., Butterbur, Quercetin): These should be discontinued before diagnostic testing as they may interfere with the results in the same way as pharmaceutical antihistamines.

Artemisia Argyi Leaf extract does not interfere with standard blood chemistry or hematology tests. However, it will directly affect:

• Skin Prick Tests: Causes a wheal and flare response.
• In Vitro Allergy Tests (e.g., RAST or ImmunoCAP): Successful immunotherapy will eventually cause a decrease in IgE levels and an increase in IgG4 levels specific to Artemisia Argyi.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Artemisia Argyi Leaf extract must NEVER be used in the following circumstances:

1. 1Severe, Unstable, or Uncontrolled Asthma: Patients whose asthma is not well-managed are at an extremely high risk of fatal bronchospasm during an allergic reaction to the extract. If the FEV1 (Forced Expiratory Volume) is consistently below 70% of predicted, immunotherapy is usually contraindicated.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The risk of a systemic reaction causing cardiac stress is too high.
3. 3Hypersensitivity to Extract Components: If a patient has had a previous near-fatal reaction to Artemisia Argyi Leaf extract specifically, they should not receive it again unless under extreme desensitization protocols in an ICU setting.
4. 4Beta-Blocker Therapy: As noted in the interactions section, the inability to respond to epinephrine makes immunotherapy unacceptably risky.

Conditions requiring a careful risk-benefit analysis include:

• Pregnancy: While not an absolute contraindication, immunotherapy is almost never started during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen). If a woman is already on a stable maintenance dose, it may be continued.
• Severe Atopic Dermatitis: Extensive skin disease can make the interpretation of diagnostic skin tests impossible.
• Autoimmune Diseases: Potential for exacerbation of the underlying disease.
• Maligancy: Patients with active cancer may have altered immune systems that respond unpredictably to immunotherapy.

Patients allergic to Artemisia Argyi Leaf may show cross-sensitivity to other members of the Asteraceae (Compositae) family. This includes:

• Ragweed (Ambrosia)
• Dandelion
• Chrysanthemums
• Sunflowers
• Chamomile

If a patient has a known severe allergy to any of these, healthcare providers should use extra caution when testing with Artemisia Argyi Leaf.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Artemisia Argyi Leaf.

Artemisia Argyi Leaf extract is classified by the FDA as Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm or affect reproduction capacity.

Key Considerations:

• Initial Testing/Treatment: It is clinical standard practice to avoid starting new allergy testing or immunotherapy during pregnancy. The risk of a systemic reaction (anaphylaxis) in the mother can lead to uterine contractions and fetal hypoxia (depriving the baby of oxygen), which can be fatal to the fetus.
• Maintenance Therapy: If a patient is already on a well-tolerated maintenance dose of Artemisia Argyi Leaf extract and becomes pregnant, the physician may choose to continue the injections at the same or a slightly reduced dose, as the risk of a reaction is lower once maintenance is reached.

It is not known whether the allergenic proteins or their metabolites are excreted in human milk. However, because these are large proteins that are broken down in the mother's body, it is highly unlikely that they would reach the infant in any significant or active form through breast milk. The American Academy of Allergy, Asthma & Immunology (AAAAI) generally considers immunotherapy to be compatible with breastfeeding.

• Approved Age: Allergenic extracts are used in children as young as 5 years old. Use in children under 5 is rare because of the difficulty in communicating symptoms of an impending reaction.
• Growth Effects: There is no evidence that Artemisia Argyi Leaf extract affects growth or development in children.
• Considerations: Children with severe eczema or asthma must be monitored even more closely than adults.

Patients over the age of 65 may be at increased risk when receiving Artemisia Argyi Leaf extract due to:

• Co-morbidities: Higher likelihood of underlying coronary artery disease or hypertension.
• Medications: Higher likelihood of taking beta-blockers or ACE inhibitors.
• Physiological Reserve: Reduced ability to survive a severe anaphylactic event.

For these reasons, the decision to use immunotherapy in the elderly is made on a strict case-by-case basis.

There are no specific guidelines for renal impairment. Since the extract is composed of proteins that undergo proteolytic degradation rather than primary renal clearance of an intact drug, no dose adjustment is typically required. However, severe renal disease may affect the body's ability to handle the physiological stress of an allergic reaction.

No dosage adjustments are necessary for patients with hepatic impairment. The liver is not involved in the primary metabolism of these allergenic extracts.

> Important: Special populations require individualized medical assessment. Always inform your allergist if you are pregnant, planning to become pregnant, or have any chronic organ disease.

Artemisia Argyi Leaf extract works through the modulation of the adaptive immune system. The primary allergenic component is Art a 1, a defensin-like protein.

1. 1Diagnostic: The proteins cross-link IgE on the surface of cutaneous mast cells, leading to the release of histamine and the formation of a wheal-and-flare.
2. 2Therapeutic: Immunotherapy induces the production of Regulatory T-cells (Tregs). These cells secrete IL-10 and TGF-beta, which suppress the Th2 allergic response. This leads to 'class switching' in B-cells, which stop producing IgE and start producing IgG4. IgG4 acts as a 'blocking antibody,' neutralizing the Artemisia allergens before they can reach the IgE on mast cells.

• Onset of Action: For diagnostic testing, the reaction occurs within 15-20 minutes. For immunotherapy, clinical improvement in symptoms typically takes 6 to 12 months of regular injections.
• Duration of Effect: The diagnostic wheal resolves within 2 hours. The therapeutic effects of a full 3-5 year course of immunotherapy can last for several years after the treatment is discontinued.
• Tolerance: Unlike many drugs, 'tolerance' in this context is the desired outcome (immunological tolerance to the allergen).

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Administered locally/subcutaneously) |

| Protein Binding | N/A (The drug itself is a mixture of proteins) |

| Half-life | Variable (Proteins degraded over hours/days) |

| Tmax | 15-30 minutes (for local reaction) |

| Metabolism | Proteolytic degradation by ubiquitous proteases |

| Excretion | Renal (as small peptide fragments) |

• Composition: A complex aqueous extract containing proteins, glycoproteins, and carbohydrates.
• Solubility: Highly soluble in water or saline-glycerin mixtures.
• Standardization: Non-standardized. Potency is measured in PNU (Protein Nitrogen Units) or w/v (weight of raw material per volume of solvent).

Artemisia Argyi Leaf is classified as a Non-Standardized Plant Allergenic Extract. Related medications include other weed extracts like Short Ragweed (Ambrosia artemisiifolia) and English Plantain (Plantago lanceolata).